Our robust research and development program is centered around Y90 radioembolization, also known as Selective Internal Radiation Therapy (SIRT) or Trans-arterial Radiation Therapy (TARE). This is a minimally invasive therapy for treating liver tumors. ABK’s Eye90 microspheres® proprietary technology incorporates the radiation therapy of Y90 with a novel imageable glass composition for procedure visualization via fluoroscopy, X-ray, and CT imaging modalities.

In addition to the development of imageable microspheres, our research is also addressing important procedural limitations. For example, by potentially improving tumor-targeting, and advancing imaging processing with Eye90 microspheres Precision Dosimetry™, we are taking a holistic approach to our goal of improving outcomes for patients with unresectable liver tumors.

It is a known challenge to evaluate Y90 tumor microspheres deposition in vivo. ABK Biomedical developed a standardized in vitro model, in partnership with NC State University, that captures hepatic vascular anatomy and matches physiologic pressures and flow rates.

In this model, the tumor is represented by a branched vascular structure which simulates HCC tumors down to the arteriole level (18µm). Researchers compared in vitro microsphere distribution between the ABK dual-syringe delivery system (DS) and the typical glass Y90 bolus delivery system (BD).

The ABK DS system delivered a greater number of glass microspheres penetrating distally, and a more uniform distribution compared to BD.